Press release
Navigating the Future: Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends and Forecast Insights, 2025 Edition
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size Growth Forecast: What to Expect by 2025?
The market for therapeutics and diagnostics in exocrine pancreatic insufficiency (EPI) has significantly expanded in recent years. The market value aims to rise from $5.69 billion in 2024 to $6.17 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%. The historical growth can be credited to the escalating prevalence of pre-existing conditions, advancement in diagnostic apparatus, pharmaceutical innovations, and the increased accessibility to global healare.
How Will the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size Evolve and Grow by 2029?
Anticipating a robust growth in the coming years, the market size for therapeutics and diagnostics in exocrine pancreatic insufficiency (EPI) is expected to surge to $8.32 billion by 2029, with a compound annual growth rate (CAGR) of 7.8%. The growth in this predicted period can be related to factors such as the advent of telemedicine and remote monitoring, the influence of data analytics and AI, enhancements in patient education and support, along with changes in regulatory and reimbursement policies. The future trend projections for this period incorporate customized treatment plans, the advent of pioneering therapies, least invasive diagnostic methods, and cooperative care models.
View the full report here:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report
What Drivers Are Propelling the Growth of Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Forward?
The rise in diabetes cases is likely to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes, a long-term metabolic disorder, is marked by consistently high blood sugar levels. Insufficiency in insulin production or utilisation causes this ailment. EPI treatment through pancreatic enzyme replacement therapy (PERT) can aid in nutrient absorption in individuals with diabetes and EPI, and it can also assist in better control of blood sugar levels. For instance, The National Health Service (NHS England), a healare system funded by the public in the UK, reported in June 2024 that the number of people identified with pre-diabetes in 2023 had risen by 18% to 3,615,330, up from 3,065,825 in 2022. Furthermore, diabetes cases in people under 40 have increased nearly 25%, rising from 173,166 in 2022 to 216,440 in 2023. Hence, the rise in diabetes cases is pushing the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is also being driven by a surge in gastrointestinal diseases. These are medical issues that affect the organs involved in digestion, known as the gastrointestinal tract. The primary role of EPI therapeutics and diagnostics is to treat gastrointestinal diseases by addressing the enzyme deficiency at its root and aiding in the smooth digestion of nutrients. An example of this is a report by Crohn's and Colitis Canada, a non-profit organization, in June 2023, which estimated that over 322,600 Canadians, or around 0.82% of the population, had inflammatory bowel diseases (IBD) in 2023. It projected that by 2035, approximately 470,000 Canadians or around 1.1% of the population, would have IBD, equivalent to 1 in every 91 people in the country. Therefore, the surge in gastrointestinal diseases is predicted to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
Which Emerging Trends Are Transforming the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market in 2025?
Major firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics sector are turning towards strategic partnerships as a way to advance technological integration and broaden their market footprint. Essentially, a strategic partnership is a cooperation between two or more entities who pool their resources and knowledge to work towards shared goals. For example, in February 2023, US protein engineering firm Codexis, Inc. and science of nutrition company Nestlé Health Science, headquartered in Switzerland, disclosed preliminary results from their Phase 1 CDX-7108 clinical trial, a potential treatment for EPI. The insights gained from this trial lay the groundwork for future research that could notably enhance treatment solutions for patients afflicted with EPI.
What Are the Key Segments in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented -
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Modifications, Nutritional s
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
Who Are the Key Players Shaping the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market's Competitive Landscape?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
What Geographic Markets Are Powering Growth in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Navigating the Future: Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends and Forecast Insights, 2025 Edition here
News-ID: 4122010 • Views: …
More Releases from The Business Research Company
Competitive Analysis: Leading Companies and New Entrants in the Wire Arc Additiv …
The wire arc additive manufacturing cell market is rapidly gaining traction as industries increasingly embrace advanced metal 3D printing technologies. With significant investments and technological breakthroughs, this sector is set to experience remarkable growth, transforming manufacturing processes across multiple fields. Let's explore the market's size, influential players, key trends, and segmentation to understand its future trajectory.
Projected Expansion of the Wire Arc Additive Manufacturing Cell Market
The wire arc additive manufacturing cell…
Future Perspectives: Key Trends Shaping the Viscosupplementation Treatment for A …
The viscosupplementation treatment for arthritis market is on the verge of significant expansion, driven by advances in medical technology and a growing demand for effective arthritis therapies. With increasing awareness around early intervention and new treatment options, this sector is poised for rapid development over the coming years. Let's explore the market size, key players, emerging trends, and segment-wise forecasts that define this growing industry.
Projected Market Growth and Size of…
Segmentation, Major Trends, and Competitive Overview of the Viral Vector Develop …
The viral vector development service market is set to experience substantial growth in the coming years, driven by technological progress and increasing demand from various sectors. As gene therapies and advanced treatments gain prominence, the need for efficient viral vector production and development is becoming more critical. Let's explore the market size projections, key players, emerging trends, and the segment structure shaping this industry's future.
Projected Expansion and Market Size of…
Competitive Landscape: Leading Companies and New Entrants in the Transient Elast …
The transient elastography market is poised for substantial expansion as advancements in healthcare diagnostics continue to evolve. Increasing emphasis on non-invasive techniques and early disease detection is driving widespread adoption, setting the stage for strong market growth in the coming years. Let's explore the current market valuation, leading players, emerging innovations, and key segments shaping this industry.
Projected Market Value and Growth of the Transient Elastography Market
The transient elastography market is…
More Releases for EPI
Emerging Trends to Reshape the Silicon EPI Wafer Market: Next-Generation Silicon …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Silicon EPI Wafer Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of the silicon epi wafer has experienced consistent expansion in the previous years, seeing a projected rise from a value of $1.8 billion in 2024 to $1.89 billion in 2025. This…
Consumer Electronics Adoption Fuels The Silicon Epi Wafer Market: Core Growth En …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Silicon EPI Wafer Industry Market Size Be by 2025?
Over recent years, the market size for silicon EPI wafers has seen considerable growth. Predictions indicate an increase from $1.8 billion in 2024 to $1.92 billion in 2025, representing a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this historical…
Evolving Market Trends In The Silicon EPI Wafer Industry: Next-Generation Silico …
The Silicon EPI Wafer Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Silicon EPI Wafer Market Size During the Forecast Period?
In recent times, the silicon EPI wafer market has witnessed substantial growth. The market size, which stood at $1.8 billion in…
EPI Invests $1 Million USD in the EPI Data Center Futurist Scholarship Program
Singapore (15 June 2023) - EPI, the global leader in data center training, audit & certification, is proud to announce the launch of the EPI Data Center Futurist Scholarship program, accompanied by a significant investment of one (1) million US-Dollar. This transformative initiative aims to provide aspiring professionals with the resources and support they need to acquire the specialized knowledge and skills necessary for success in the dynamic data…
Epi Wafer Market to Surpass Valuation of US$ 5.8 Bn by 2030 with Rising Demand f …
The global Epi Wafer market is estimated to attain a valuation of US$ 5.8 billion by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6% during the forecast period, 2021-2031.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of…
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease.
Download the sample report at: https://www.pharmaproff.com/request-sample/1024
Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI…
